Bolt Biotherapeutics Inc. (BOLT)
NASDAQ: BOLTHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
BOLT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.03M
- EPS (TTM)
- -$16.51
- Dividend yield
- None
- 52-week range
- 3.10 – 7.20
- Day range
- 3.50 – 3.65
- Volume / Avg
- 10.45K / 26.26K
- Beta
- —
- Shares outstanding
- 1.93M
52-week range
BOLT stock today
On Oct 8, BOLT ended the session at $3.65, adding $0.05 (1.39%), versus the S&P 500's 0.47% decline. Trading was light, with 10.45K shares changing hands, about 40% of the average daily volume. Shares are 49.3% below their 52-week high of $7.20 and 17.7% above the 52-week low of $3.10, near the bottom of the past year's range.
Bolt Biotherapeutics has posted a net loss over the last twelve months (EPS of -$16.51), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Bolt Biotherapeutics
Company profileBolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. William P. Quinn
- Headquarters
- Redwood City, CA
- Employees
- 23
- IPO year
- 2021
- Website
- boltbio.com
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$29.00+694.52%
- Strong buy 0
- Buy 2
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Bolt Biotherapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ACXPAcurx Pharmaceuticals Inc. | 1.25 | -3.85% | $6.95M | vs BOLT |
| APREAprea Therapeutics Inc. | 0.5582 | -7.74% | $7.03M | vs BOLT |
| ENVBEnveric Biosciences Inc. | 1.52 | +1.67% | $6.80M | vs BOLT |
| NRSNNeuroSense Therapeutics Ltd. | 3.58 | -6.28% | $6.79M | vs BOLT |
| LEXXLexaria Bioscience Corp. | 3.20 | -8.57% | $6.74M | vs BOLT |
| AIMAIM ImmunoTech Inc. | 0.1796 | -1.75% | $7.17M | vs BOLT |
| XCURExicure Inc. | 1.00 | -1.96% | $6.55M | vs BOLT |
| CELZCreative Medical Technology Holdings Inc. | 0.8604 | -2.45% | $6.53M | vs BOLT |
Indexes, lists and sector
Appears in lists
Bolt Biotherapeutics stock FAQ
What is Bolt Biotherapeutics's stock price today?
BOLT last traded at $3.65 as of Oct 8, 4:00 PM EDT, up 1.39% on the day. Prices are delayed at least 15 minutes.
Who is Bolt Biotherapeutics's CEO?
Mr. William P. Quinn is the chief executive officer of Bolt Biotherapeutics Inc., which has about 23 employees.
What is the BOLT 52-week high?
The 52-week high for BOLT is $7.20 and the 52-week low is $3.10. The stock is currently 49.3% below its high.